N1: CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice

Sponsor

CureOne (Other)

Overall Status

Terminated

CT.gov ID

NCT02900248

Collaborator

(none)

Enrollment

Location

17.8

Actual Duration (Months)

1.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Registry participants with advanced malignancy or myelodysplasia will have a sample of their tumor or tissue analysed for genetic alterations using next generation sequencing (NGS) performed in a lab that has been certified to meet a high quality standard. Treatments and outcomes will be reported to the registry to allow further understanding of how genetic differences can lead to better diagnosis and treatments.

Condition or Disease	Intervention/Treatment	Phase
Neoplasms Lung Neoplasms Colon Neoplasms Breast Neoplasms Pancreatic Neoplasms Prostate Neoplasms Kidney Neoplasms Liver Neoplasms Rectal Neoplasms Hematologic Neoplasms Multiple Myeloma Myelodysplastic Syndromes Ovarian Neoplasms Bladder Neoplasms Testicular Neoplasms Endometrial Neoplasms Brain Neoplasms Biliary Tract Neoplasms Head and Neck Neoplasms Uterine Cervical Neoplasms Skin Neoplasms Melanoma Gastric Neoplasms Anal Neoplasms Sarcoma	Other: Provider determined

Detailed Description

Every malignancy or myelodysplasia is different on a molecular (genetic) level even in patients with the same diagnosis. These differences often give prognostic information, determine what types of treatments are available for a patient, as well as determine outcomes. In this registry, the method of identifying the genetic difference of the disease (using Next Generation Sequencing or NGS) is standardized, the treatments received by a patient, and the outcome of these treatments are entered into a database where all identifying information is removed.

Payers (insurance companies) or others will generally pay for the testing, laboratories will report the genetic information, physicians and eventually patients will report treatments and outcomes. This information will then be reviewed frequently and analyzed to find better methods to improve the testing or treatments of disease.

It is expected that dozens of other trials or registries will eventually be available for participants.

Study Design

Study Type:

Observational [Patient Registry]

Actual Enrollment :

23 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Patients Diagnosed With Advanced Malignancy or Myelodysplasia, Tested by Standardized Sequencing, and Treated by Physician-Determined Care Plan: A CureOne Observational Registry (N1)

Actual Study Start Date :

Oct 2, 2017

Actual Primary Completion Date :

Mar 29, 2019

Actual Study Completion Date :

Mar 29, 2019

Arms and Interventions

Arm	Intervention/Treatment
Provider Determined Treatment Participants with advanced solid or hematologic malignancy or myelodysplasia (MDS), will have their tumor or tissue tested by a standardized next generation sequencing (NGS) panel. They will be treated by physician determined treatment including FDA approved or compendia-listed biomarker directed therapy. All patients will be followed for time to progression by line of therapy, overall survival by line of therapy.	Other: Provider determined Provider will treat patient as he/she feels best

Arm

Intervention/Treatment

Provider Determined Treatment

Participants with advanced solid or hematologic malignancy or myelodysplasia (MDS), will have their tumor or tissue tested by a standardized next generation sequencing (NGS) panel. They will be treated by physician determined treatment including FDA approved or compendia-listed biomarker directed therapy. All patients will be followed for time to progression by line of therapy, overall survival by line of therapy.

Other: Provider determined

Provider will treat patient as he/she feels best

Outcome Measures

Primary Outcome Measures

Best Overall Response [5 years]
Best overall response by line of therapy and biomarker
Time to Treatment Progression [5 years]
Physician-determined Time to Treatment Progression by line of therapy and method of determining progression (worsening of disease, new lesions, clinical decline, and/or other).

Secondary Outcome Measures

Overall Survival [5 years]
Overall survival by biomarker
Establish stable estimates of biomarker prevalence in patients with advanced malignancies in a large population. [5 years]
Establish stable estimates of biomarker prevalence in patients with advanced malignancies in a large population.
To determine rate of enrollment into existing and future therapeutic clinical trials. [5 years]
To determine rate of enrollment into existing and future therapeutic clinical trials.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion:

Patient is ≥ 18 years old.
Patient is able to understand and agrees to comply with the requirements of the study and provides written informed consent indicating voluntary consent to participate in the registry. If the patient is unable to provide consent, but is able to comply with other study requirements, informed consent must be obtained by a durable power of attorney or healthcare proxy.
Patient is diagnosed with any of the following malignancies or disorders AND with the corresponding American Joint Commission on Cancer (AJCC) 7th Edition Staging OR listed clinical scenario (i.e. a patient initially diagnosed with early stage lung cancer would not be a candidate, but if they later developed metastatic disease, they would be eligible and could be enrolled in this registry):
Solid Malignancies Tumor Type (Initial Stage: Clinical Scenario) Lung and

Bronchus (Stage IIIB or IV: Metastatic or Extensive) Colorectal (Stage IVB:

Metastatic) Pancreas (Stage IV: Metastatic) Breast (Stage IV: Metastatic)

Prostate (Stage IV: Castrate resistant) Hepatobiliary (Non-resectable:

Metastatic) Tumor of Unknown Primary (Non-resectable: Initial Diagnosis) Bladder (Stage IV: Metastatic) Esophageal (Stage IV: Metastatic) Brain and CNS (All: Initial Diagnosis) Ovarian Cancer (Stage IV or Non-resectable: Recurrent) Kidney or Renal Pelvis (Stage IV: Metastatic) Stomach (Stage IV: Metastatic) Endometrial (Stage IV: Metastatic) Melanoma (Stage IV: Metastatic) Oral Cavity and Pharynx (Stage IVC: Metastatic) Less common Solid Malignancies* (Stage IV: Metastatic)

*Defined as <1% annual death rate in the SEER database. This also includes histologies of common tumors that have been shown to have a more aggressive phenotype and require a different treatment approach than their more common counterparts.

Hematologic Malignancies Tumor Type (Initial Stage: Clinical Scenario) Non-Hodgkins Lymphoma (N/A: Progressed or relapsed after initial treatment) Multiple Myeloma (Non-smoldering disease: Requiring Treatment) Acute Myelogenous

Leukemia (N/A: Initial Diagnosis or Relapse) Chronic Lymphocytic Leukemia (N/A:

Progressed or relapsed after initial therapy) Acute Lymphoblastic Leukemia (N/A:

Initial Diagnosis or Relapse) Hodgkins Lymphoma (N/A: Progressed or relapsed after initial therapy) Chronic Myelogenous Leukemia (N/A: Progressed or relapsed after initial therapy) Less common Hematologic Malignancies (N/A: Requiring Treatment)

Myelodysplasia with cytopenias at time of requiring treatment
Unless otherwise specified, all participants will have NGS testing of an appropriate somatic tissue specimen (biopsy tissue or cell-free DNA) at a CureOne approved lab using the testing outlined in the protocol. The specimen used for testing must have been obtained within 6 months (180 days) preceding consent or on a specimen(s) obtained within 3 months (90 days) following consent to participate in this observational registry. Any non-registry biomarker testing must also be reported. Patient will be treated by physician-determined care plan.
Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at initial screening.
Patient is willing and able to be treated by physician-determined care plan.
Patient may participate in other clinical studies or registries while participating in this observational registry.
Patient agrees with regular follow up (see Assessment Schedule below).

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Teton Cancer Institute	Idaho Falls	Idaho	United States	83404

Sponsors and Collaborators

CureOne

Investigators

Principal Investigator: Razelle Kurzrock, M.D., Moores Cancer Center, University of California at San Diego
Study Chair: John Pfeifer, M.D., Ph.D., Washington University School of Medicine
Study Director: Dane J. Dickson, M.D., CureOne/Knight Cancer Center, Oregon Health and Science University